HCmed Innovations Co (TPE:6934) Altman Z-Score: 8.57 (As of Jul. 06, 2026) — 65% Below Median


TPE:6934 HCmed Innovations Co Ltd TPE:6934
11 GF Score
Price NT$68.00
! 4 Warning Signs
View Full Analysis

What is HCmed Innovations Co Altman Z-Score?

HCmed Innovations Co TPE:6934 -2.16% 11 Altman Z-Score is 8.57 as of Jul. 06, 2026, which is 65% below its 10-year median of 24.68. GuruFocus rates TPE:6934 with a GF Score™ of 11/100. The stock has 4 warning signs investors should review. Among 809 Medical Devices & Instruments companies, HCmed Innovations Co ranks better than 79.73% on this metric.

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Good Sign:

Altman Z-score of 8.78 is strong.

HCmed Innovations Co has a Altman Z-Score of 8.57, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for HCmed Innovations Co's Altman Z-Score or its related term are showing as below:

TPE:6934' s Altman Z-Score Range Over the Past 10 Years
Min: 8.78   Med: 24.68   Max: 38.97
Current: 8.78

During the past 5 years, HCmed Innovations Co's highest Altman Z-Score was 38.97. The lowest was 8.78. And the median was 24.68.


HCmed Innovations Co  (TPE:6934) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


HCmed Innovations Co Altman Z-Score Related Terms


HCmed Innovations Co Altman Z-Score Historical Data

* Premium members only.

The historical data trend for HCmed Innovations Co's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HCmed Innovations Co Altman Z-Score Chart

HCmed Innovations Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z-Score
0.00 0.00 0.00 38.97 10.38

HCmed Innovations Co Quarterly Data
Dec21 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.35 38.97 18.70 13.23 10.38

TPE:6934 vs ABT, SYK, MDT: Altman Z-Score Comparison

For the Medical Devices subindustry, HCmed Innovations Co's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HCmed Innovations Co Altman Z-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, HCmed Innovations Co's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where HCmed Innovations Co's Altman Z-Score falls into.


TPE:6934
11GF Score
HCmed Innovations Co Ltd TPE:6934
Altman Z-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HCmed Innovations Co Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

HCmed Innovations Co's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.5163+1.4*-1.5053+3.3*0.0229+0.6*15.9094+1.0*0.441
=8.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2025:
Total Assets was NT$441.19 Mil.
Total Current Assets was NT$287.56 Mil.
Total Current Liabilities was NT$59.77 Mil.
Retained Earnings was NT$-664.12 Mil.
Pre-Tax Income was 6.952 + -36.108 + 0 + 38.252 = NT$9.10 Mil.
Interest Expense was -0.561 + -0.398 + 0 + -0.044 = NT$-1.00 Mil.
Revenue was 82.48 + 6.899 + 0 + 105.189 = NT$194.57 Mil.
Market Cap (Today) was NT$2,446.15 Mil.
Total Liabilities was NT$153.76 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(287.555 - 59.769)/441.189
=0.5163

X2=Retained Earnings/Total Assets
=-664.117/441.189
=-1.5053

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(9.096 - -1.003)/441.189
=0.0229

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=2446.148/153.755
=15.9094

X5=Revenue/Total Assets
=194.568/441.189
=0.441

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

HCmed Innovations Co has a Altman Z-Score of 8.57 indicating it is in Safe Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.

Frequently Asked Questions Learn more about Altman Z-Score →
What does a Altman Z-Score of 8.57 mean?
HCmed Innovations Co (TPE:6934) has a Altman Z-Score of 8.57 as of Jul. 06, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on HCmed Innovations Co and its competitors. This is 65% below median its historical median of 24.68. Over the past decade, HCmed Innovations Co's Altman Z-Score has ranged from 8.78 to 38.97. According to the industry distribution chart, HCmed Innovations Co ranks #164 out of 809 companies in the Medical Devices & Instruments industry, placing it in the top 20.3%.
Is HCmed Innovations Co's Altman Z-Score too high?
HCmed Innovations Co's current Altman Z-Score of 8.57 is 65% below median its 10-year median of 24.68. Over the past 10 years, this metric has ranged from a low of 8.78 to a high of 38.97. The Medical Devices & Instruments industry median Altman Z-Score is 3.02. HCmed Innovations Co's value of 8.57 is 183.8% above this industry median. Based on the distribution chart, HCmed Innovations Co ranks #164 out of 809 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, HCmed Innovations Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does HCmed Innovations Co's Altman Z-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HCmed Innovations Co ranks #164 out of 809 companies for Altman Z-Score. This places HCmed Innovations Co in the top 20% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 3.02. HCmed Innovations Co's value of 8.57 is 183.8% above this benchmark. Historically, HCmed Innovations Co's own Altman Z-Score has ranged from 8.78 to 38.97 over the past decade. While the company's 10-year median is 24.68 vs. the industry median of 3.02, HCmed Innovations Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Devices & Instruments company?
The median Altman Z-Score among Medical Devices & Instruments companies is 3.02, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HCmed Innovations Co's current Altman Z-Score of 8.57 is 183.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on HCmed Innovations Co and its competitors. For the Medical Devices & Instruments industry, the median Altman Z-Score is 3.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCmed Innovations Co's current Altman Z-Score is 8.57, which is 65% below median its own 10-year median of 24.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCmed Innovations Co stock overvalued right now?
HCmed Innovations Co (TPE:6934) has a current Altman Z-Score of 8.57. The current Altman Z-Score is 8.57, which is 65% below median its 10-year median of 24.68 and 183.8% above the Medical Devices & Instruments industry median of 3.02. HCmed Innovations Co's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For HCmed Innovations Co (TPE:6934), the current Altman Z-Score is 8.57 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HCmed Innovations Co Business Description

Address Dunhua S. Road, Rm.B, 10th floor., No.319, Sec.2, Taipei, TWN, 106033
HCmed Innovations Co Ltd is engaged in designing, developing, manufacturing and selling drug delivery system. It is focused on inhalation therapy to create integrated drug nebulizer combination products featuring nebulization therapeutic drugs that include small molecule synthetics and large molecule biologics, as either solutions, suspensions, and even difficult-to-deliver high viscosity drugs. Its product includes Pulmogine. Geographically, the company operates in America, Europe, Asian and African regions.
11GF Score

Get the complete analysis for TPE:6934

Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$68.00
Price